1-O-hexadecyl-2-N-methylcarbamol -sn-glycerol-3-phosphocholine: PAF analog found in rabbit cornea; induces collagenase expression in corneal epithelial cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 124663 |
| CHEMBL ID | 1599651 |
| SCHEMBL ID | 5501409 |
| MeSH ID | M0221642 |
| Synonym |
|---|
| L120 , |
| [(2r)-3-hexadecoxy-2-(methylcarbamoyloxy)propyl] 2-trimethylazaniumylethyl phosphate |
| mc-paf |
| methylcarbamyl paf |
| methyl-carbamyl platelet-activating factor |
| gtpl3427 |
| NCGC00161384-01 |
| NCGC00161384-02 |
| NCGC00161384-03 |
| HMS1989A04 |
| methylcarbamol |
| c-paf |
| BML3-F03 |
| [(2r)-3-hexadecoxy-2-(methylcarbamoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate |
| HMS1361A04 |
| HMS1791A04 |
| 91575-58-5 |
| 4,7,9-trioxo-2-aza-8-phosphaundecan-11-aminium, 5-((hexadecyloxy)methyl)-8-hydroxy-n,n,n-trimethyl-3-oxo-, hydroxide, inner salt, 8-oxide, (r)- |
| 5-((hexadecyloxy)methyl)-8-hydroxy-n,n,n-trimethyl-3-oxo-4,7,9-trioxo-2-aza-8-phosphaundecan-11-aminium hydroxide, inner salt, 8-oxide, (r)- |
| 1-o-hexadecyl-2-n-methylcarbamol -sn-glycerol-3-phosphocholine |
| cpaf |
| mcplatelet activating factor |
| c-paf (carbamyl-paf ) |
| SCHEMBL5501409 |
| CHEMBL1599651 |
| 1-o-hexadecyl-2-n-methylcarbamyl-sn-glycero-3-phosphocholine |
| 1-o-hexadecyl-2-o-(n-methylcarbamoyl)-sn-glyceryl-3-phosphorylcholine |
| methylcarbamyl paf c-16 |
| HMS3402A04 |
| HMS3648P12 |
| AKOS027379118 |
| 1-o-palmitol-2-(n-methylcarbamyl)-sn-glycero-3-phospho-choline |
| Q27085367 |
| (r)-3-(hexadecyloxy)-2-(methylcarbamoyloxy)propyl 2-(trimethylammonio)ethyl phosphate |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 4.4668 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 31.6228 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| TDP1 protein | Homo sapiens (human) | Potency | 2.6493 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 0.2993 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 2.8184 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (31.82) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||